News | November 07, 2011

Second-Generation Bioresorbable Stent Promotes Lumen Enlargement

November 7, 2011 – Arterial Remodeling Technologies (ART) reported that in vivo data strongly suggest that its second-generation bioresorbable stent promotes positive arterial remodeling in a post-angioplasty porcine model at three months follow-up. In addition, acute safety data are excellent: there have been more than 250 MACE-free consecutive implantations of its bioresorbable stent in its preclinical phase of development.

ART also reported that it has appointed interventional cardiologist Jean Fajadet, M.D., to its scientific advisory board. Fajadet is co-director of interventional cardiology at Clinique Pasteur, Toulouse, France, and president of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

“We are extremely pleased to have Dr. Fajadet, a key international opinion leader in interventional cardiology, join ART’s scientific advisory board,” said Machiel van der Leest, CEO.  “Dr. Fajadet will play a critical role as we move toward our First-in-Human milestone with our second-generation bioresorbable stent.”\

ART’s bioresorbable stent is designed to provide a transient effective scaffold that dismantles and relinquishes its primary mechanical scaffolding function after three months. According to van der Leest, who has developed and successfully introduced 15 Class III medical devices during his career, this three-month scaffolding period is commonly recognized by experts as the requisite length of time necessary to allow the healing process to stabilize the artery following the trauma generated by angioplasty, and to avoid recoil and constrictive remodeling. Extensive in vivo data demonstrate that ART’s polymer is designed to be safe while triggering only a minimal inflammatory response that is typical for biocompatible resorption processes.

“The key characteristics of ART’s second-generation bioresorbable stent are that it is made of non-aggressive material, has a programmed transitory presence, and — most important — facilitates natural remodeling,” said Antoine LaFont, M.D., Ph.D., professor of medicine, head of the Interventional Cardiology Department, Georges Pompidou Hospital (Paris), and past chairman, Interventional Cardiology Working Group, European Society of Cardiology (ESC).  LaFont is a co-founder of ART.

ART’s novel biopolymers have been developed in conjunction with one of the world’s leading authorities in bioresorbable polymers, research professor Michel Vert, Ph.D., who is former director of the Research Center for Artificial Biopolymers at France’s National Center for Scientific Research (Centre National de Recherche Scientifique/CNRS). Vert is a co-founder of ART.

For more information: www.art-stent.com

 

 

Related Content

Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Overlay Init